Description
Raloxifene is classified as a selective estrogen receptor modulator and is currently being researched as an anti-catabolic and muscle dystrophy treatment in postmenopausal women with osteoporosis. It functions through binding to estrogen receptors which activate the estrogenic pathways and blockades in tissues